Alterity CEO disposes 47,620 options at $0.50
ATHE’s CEO and director reported the disposal of a 47,620-contract listed option position linked to Alterity’s ordinary shares.
Rhea-AI Filing Summary
ALTERITY THERAPEUTICS LTD (ATHE) reported that Chief Executive Officer and director David Allen Stamler recorded a disposition involving derivative securities tied to the company’s ordinary shares. On August 31, 2026, he reported a transaction in 47,620 listed options expiring August 31, 2026 at a reported price of $0.50 per option, with 47,620 underlying ordinary shares. Following the transaction, this listed option position is shown as 0 derivative securities held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 47,620 shares
Net Buy
1 txn
Insider
Stamler David Allen
Role
Chief Executive Officer
Bought
47,620 shs ($24K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Listed option exp 31 Aug 2026 | 47,620 | $0.50 | $24K |
Holdings After Transaction:
Listed option exp 31 Aug 2026 — 0 contracts (Direct)
Key Figures
Listed options transacted: 47,620 options
Reported price per listed option: $0.50 per option
Underlying ordinary shares: 47,620 shares
+4 more
7 metrics
Listed options transacted
47,620 options
Derivative transaction reported for August 31, 2026
Reported price per listed option
$0.50 per option
Derivative transaction on August 31, 2026
Underlying ordinary shares
47,620 shares
Shares underlying the listed options expiring August 31, 2026
Post-transaction listed option holdings
0 options
Total derivative securities of this listed option series held directly after transaction
Conversion or exercise price
$0.50 per share
Exercise price of the listed options expiring August 31, 2026
Option expiration date
August 31, 2026
Expiration date of the listed options involved in the transaction
Option exercise date
April 15, 2026
Exercise date field for the listed options tied to ordinary shares
Key Terms
Listed option, underlying security, derivative securities, Rule 10b5-1
4 terms
Listed option financial
"Security title is given as “Listed option exp 31 Aug 2026”"
underlying security financial
"The filing names the underlying security title as “Ordinary shares”"
derivative securities financial
"The transaction is classified as involving derivative securities"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
Rule 10b5-1 regulatory
"A document-level Rule 10b5-1 checkbox indicates plan status"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
FAQ
What insider transaction did ATHE’s CEO report on this Form 4?
David Allen Stamler, ATHE’s Chief Executive Officer and director, reported a disposition involving 47,620 listed options tied to Alterity Therapeutics’ ordinary shares, with the transaction date reported as August 31, 2026.
What was the size and price of the derivative position reported for ATHE?
The filing shows a transaction in 47,620 listed options with a reported price of $0.50 per option. Each option relates to one underlying ordinary share, for 47,620 underlying shares in total.
What type of security was involved in the ATHE Form 4 transaction?
The transaction involved a derivative security described as a “Listed option exp 31 Aug 2026”, with an underlying security title of “Ordinary shares” of Alterity Therapeutics Ltd.
What are David Allen Stamler’s reported holdings after this ATHE option transaction?
For this specific listed option series, the Form 4 reports 0 derivative securities held directly following the transaction. The filing does not list additional derivative positions in its derivative summary.
Was the ATHE insider transaction made under a Rule 10b5-1 trading plan?
The document-level Rule 10b5-1 checkbox is not marked as affirmative, indicating the filing does not affirm that the reported transaction was made under a Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
